Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2010 1
2014 1
2016 2
2017 5
2018 6
2019 6
2020 4
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Baby food pouches and Baby-Led Weaning: Associations with energy intake, eating behaviour and infant weight status.
Cox AM, Taylor RW, Haszard JJ, Beck KL, von Hurst PR, Conlon CA, Te Morenga LA, Daniels L, McArthur J, Paul R, McLean NH, Jones EA, Katiforis I, Brown KJ, Gash M, Rowan M, Fleming EA, Jupiterwala R, Bruckner BR, Heath AM. Cox AM, et al. Among authors: brown kj. Appetite. 2024 Jan 1;192:107121. doi: 10.1016/j.appet.2023.107121. Epub 2023 Nov 14. Appetite. 2024. PMID: 37972656 Free article.
Adherence to Infant Feeding Guidelines in the First Foods New Zealand Study.
Brown KJ, Beck KL, von Hurst P, Heath AL, Taylor R, Haszard J, Daniels L, Te Morenga L, McArthur J, Paul R, Jones E, Katiforis I, Rowan M, Casale M, McLean N, Cox A, Fleming E, Bruckner B, Jupiterwala R, Wei A, Conlon C. Brown KJ, et al. Nutrients. 2023 Nov 2;15(21):4650. doi: 10.3390/nu15214650. Nutrients. 2023. PMID: 37960303 Free PMC article.
Nutritional Implications of Baby-Led Weaning and Baby Food Pouches as Novel Methods of Infant Feeding: Protocol for an Observational Study.
Taylor RW, Conlon CA, Beck KL, von Hurst PR, Te Morenga LA, Daniels L, Haszard JJ, Meldrum AM, McLean NH, Cox AM, Tukuafu L, Casale M, Brown KJ, Jones EA, Katiforis I, Rowan M, McArthur J, Fleming EA, Wheeler BJ, Houghton LA, Diana A, Heath AM. Taylor RW, et al. Among authors: brown kj. JMIR Res Protoc. 2021 Apr 21;10(4):e29048. doi: 10.2196/29048. JMIR Res Protoc. 2021. PMID: 33881411 Free PMC article.
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
Huhn GD, Wilkin A, Mussini C, Spinner CD, Jezorwski J, El Ghazi M, Van Landuyt E, Lathouwers E, Brown K, Baugh B; AMBER and EMERALD study groups. Huhn GD, et al. Among authors: brown k. HIV Res Clin Pract. 2020 Dec;21(6):151-167. doi: 10.1080/25787489.2020.1844520. Epub 2021 Feb 2. HIV Res Clin Pract. 2020. PMID: 33528318 Free article. Clinical Trial.
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection.
Lathouwers E, Seyedkazemi S, Luo D, Brown K, De Meyer S, Wong EY. Lathouwers E, et al. Among authors: brown k. HIV Res Clin Pract. 2020 Apr-Jun;21(2-3):83-89. doi: 10.1080/25787489.2020.1794439. Epub 2020 Jul 26. HIV Res Clin Pract. 2020. PMID: 32715952
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Lathouwers E, et al. Among authors: brown k. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31516033 Free PMC article. Clinical Trial.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, DeJesus E, Petrovic R, Luo D, Van Landuyt E, Lathouwers E, Nettles RE, Brown K, Wong EY. Huhn GD, et al. Among authors: brown k. AIDS Res Ther. 2019 Aug 29;16(1):23. doi: 10.1186/s12981-019-0235-1. AIDS Res Ther. 2019. PMID: 31464642 Free PMC article. Clinical Trial.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group. Eron JJ, et al. Among authors: brown k. Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4. Antiviral Res. 2019. PMID: 31279073 Free article. Clinical Trial.
26 results